(Q35044582)

6 August 2017

1 reference

title

The myelodysplastic syndrome(s): a perspective and review highlighting current controversies (English)

1 reference

6 August 2017

2

Ayalew Tefferi

1 reference

6 August 2017

David P Steensma

1

1 reference

6 August 2017

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

27

1 reference

6 August 2017

2

1 reference

6 August 2017

95-120

1 reference

The concept of preleukemia: clinical and laboratory studies

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Language and the clonal myeloid diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Clonal lymphocytes are detectable in only some cases of MDS

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Lymphoblastic transformation of myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Acute lymphoblastic leukemia following myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

1 reference

7 January 2021

Consilience across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: common themes and emerging patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndromes may have an infectious etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplasia or myeloneoplasia: thoughts on the nosology of clonal myeloid diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The myeloproliferative disorders. An historical appraisal and personal experiences

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The 5q- syndrome: a scientific and clinical update

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Minimal diagnostic criteria for the myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Minimal diagnostic criteria for the myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Bone marrow dysplasia. A continuing diagnostic challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndrome: a search for minimal diagnostic criteria.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Dyshaemopoiesis in adults: a practical classification for diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The bone marrow aspirate of healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Alcohol-induced bone marrow damage: status before and after a 4-week period of abstinence from alcohol with or without disulfiram. A randomized bone marrow study in alcohol-dependent individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Arsenic intoxication presenting as a myelodysplastic syndrome: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The Bone Marrow in Human Immunodeficiency Virus (HIV)-Related Disease: Morphology and Clinical Correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Acute parvovirus B19 infection mimicking myelodysplastic syndrome of the bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Parvovirus B19 infection infrequently involved in children and adults with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The relationship between the myelodysplastic syndromes and the myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Mixed myelodysplastic and myeloproliferative syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Hypocellular myelodysplastic syndromes (MDS): new proposals.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndrome and aplastic anemia--diagnostic and conceptual uncertainties

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Paroxysmal nocturnal hemoglobinuria as a marker for clonal myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Towards a novel classification of human malignancies based on gene expression patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia--distinct subgroups or two stages of the same disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Problems in the classification of CMML--dysplastic versus proliferative type.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Lymphoma classification--from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA)

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Prognostic factors in the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Increased prevalence of GSTM(1) null genotype in patients with myelodysplastic syndrome: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

t(8;21) myelodysplasia, an early presentation of M2 AML

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Bone marrow dysplasia in patients with newly diagnosed acute myelogenous leukemia does not correlate with history of myelodysplasia or with remission rate and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Dyshematopoiesis in de novo acute myeloid leukemia: cell biological features and prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplasia with fibrosis: a distinct entity?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Immunological abnormalities in myelodysplastic syndromes. II. Coexistent lymphoid or plasma cell neoplasms: a report of 20 cases unrelated to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Concurrent development of preleukaemic, lymphoproliferative and plasma cell disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Epidemiologic perspectives on myelodysplastic syndromes and leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The preleukemic syndrome (hemopoietic dysplasia).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Establishing the incidence of myelodysplasia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Establishing the incidence of myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Epidemiological and etiological aspects of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Incidence of myelodysplastic syndromes in a Swedish population

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Increasing incidence of myelodysplastic syndromes: real or fictitious?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Leukemias and lymphomas: time trends in the UK, 1984-93.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Two pathways of apoptosis induced with all-trans retinoic acid and etoposide in the myeloid cell line P39.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Cytogenetically unrelated clones in therapy-related myelodysplasia and acute myeloid leukemia: experience from the Copenhagen series updated to 180 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Multiple chromosomally distinct cell populations in myelodysplastic syndromes and their possible significance in the evolution of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A multimodal approach in the diagnosis of patients with hematopoietic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

dlk inhibits stem cell factor-induced colony formation of murine hematopoietic progenitors: Hes-1-independent effect

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

TP53 mutations in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Absence of point mutations within the AML-1 gene in patients with MDS/AML and loss of chromosome 5q or 7.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Smoking and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Use of hair dyes, hematopoietic neoplasms, and lymphomas: a literature review. I. Leukemias and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Genetic analysis of familial myelodysplastic syndrome: absence of linkage to chromosomes 5q31 and 7q22

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Familial MDS with 5q- abnormality

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Fanconi anemia: myelodysplasia as a predictor of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Bloom's syndrome complicated by myelodysplastic syndrome and multiple neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Apoptosis is a Common Histopathological Finding in Myelodysplasia: the Correlate of Ineffective Haematopoiesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: the cause-effect relationship

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Is apoptosis a massive process in myelodysplastic syndromes?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Biologic characteristics of 164 patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

'Low-risk' myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2-related proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Signal antonymy unique to myelodysplastic marrows correlates with altered expression of E2F1

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

X-linked pyridoxine-responsive sideroblastic anemia due to a Thr388-to-Ser substitution in erythroid 5-aminolevulinate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Sideroblasts, Siderocytes, and Sideroblastic Anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Excessive apoptosis, increased phagocytosis, nuclear inclusion bodies and cylindrical confronting cisternae in bone marrow biopsies of myelodysplastic syndrome patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Cloning and chromosomal mapping of a novel ABC transporter gene (hABC7), a candidate for X-linked sideroblastic anemia with spinocerebellar ataxia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Twenty-six patients with hematologic disorders and X chromosome abnormalities. Frequent idic(X)(q13) chromosomes and Xq13 anomalies associated with pathologic ringed sideroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Improve or abandon the standardized response criteria for myelodysplastic syndromes recommended by the International Working Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Clarifications to the standard neutrophil response criteria for clinical trials in myelodysplastic syndromes are needed

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

High doses of intravenous recombinant erythropoietin for the treatment of anaemia in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Effects of long-term treatment with recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Pilot study of low-dose interleukin-11 in patients with bone marrow failure

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Spontaneous and cytokine-induced thrombocytopenia in myelodysplastic syndromes: serum thrombopoietin levels and bone marrow morphology. Scandinavian MDS Group, Sweden and Norway

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Thrombopoietin stimulates myelodysplastic syndrome granulocyte-macrophage and erythroid progenitor proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Gamma-interferon in myelodysplastic syndromes: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Phase I study of recombinant human interleukin-3 in patients with bone marrow failure

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of patients with low-risk myelodysplastic syndromes using a combination of all- trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Differentiation therapy of myelodysplastic syndromes: fact or fiction?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A pilot trial of 13-cis-retinoic acid and alpha-tocopherol with recombinant human erythropoietin in myelodysplastic syndrome patients with progressive or transfusion-dependent anemias. The Central Pennsylvania Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of high risk myelodysplastic syndromes with idarubicin and cytosine arabinoside supported by granulocyte-macrophage colony-stimulating factor. (GM-CSF)

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Phase II study of combination human recombinant GM-CSF with intermediate-dose cytarabine and mitoxantrone chemotherapy in patients with high-risk myelodysplastic syndromes (RAEB, RAEBT, and CMML): an Eastern Cooperative Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment with low-dose oral etoposide in patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of chronic myelomonocytic leukemia with low dose etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The maturation of differentiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Haem arginate as a treatment for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Heme arginate treatment for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Bryostatin 1: differentiating agent from the depths

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Treatment of unfavorable myelodysplastic syndrome with all-trans-retinoic acid and subcutaneous Ara C

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndrome treatment with danazol and cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor α levels

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Activity of the caspase-3/CPP32 enzyme is increased in “early stage” myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Expression and activity of caspases 1 and 3 in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Caspases and apoptosis in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Immunosuppressive therapy for hypoplastic myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Antithymocyte globulin for patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Antilymphocyte globulin for myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Management of patients with myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Red cell folate in elderly patients with myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Refractory anemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients. Cooperative Group for the Study of Aplastic and Refractory Anemias

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A review of 76 patients with myelodysplastic syndromes treated with danazol

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia): identification of responsive patients using in-vitro techniques

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Arsenic--new life for an old potion

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Thalidomide on the comeback trail

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Thalidomide--a revival story

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Thalidomide, a current teratogen in South America

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Bone marrow transplantation for myelodysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Suicide and suicidal ideation after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia (Ph1)-negative PBPC in chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Clonal analysis of peripheral blood and haemopoietic colonies in patients with aplastic anaemia and refractory anaemia using the polymorphic short tandem repeat on the human androgen-receptor (HUMARA) gene

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Refractory anaemia with preleukaemic polyclonal haemopoiesis and the emergence of monoclonal erythropoiesis on disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Non-myeloablative stem cell transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Hematopoietic stem-cell transplants using umbilical-cord blood

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Progress in clinical application of use of progenitor cells expanded with hematopoietic growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndromes: a scoring system with prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The diagnostic and prognostic value of bone marrow immunostaining in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

The prognostic impact of karyotypic subgroups in myelodysplastic syndromes is strongly modified by sex

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Myelodysplastic syndromes. Pathogenesis, diagnosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Pre-leukaemic anaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

PRELEUKEMIC ACUTE HUMAN LEUKEMIA

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Refractory normoblastic anaemia: a clinical and haematological study of seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Smoldering acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Refractory Megaloblastic Anemia with Myeloperoxidase-Deficient Neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Preleukemia. The hematologic syndrome preceding acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

Hypoplastic acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900098-X

7 January 2021

10.1016/S0145-2126(02)00098-X

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12526916